1. Introduction {#sec0005}
===============

Colorectal cancer accompanied with tumor thrombosis in the superior/inferior mesenteric vein (SMV/IMV) is quite rare \[[@bib0005]\]. Otani et al. in their review article showed that venous tumor thrombosis may be a strong risk factor for the development of liver metastasis \[[@bib0010]\]; hence, the presence of venous tumor thrombosis may influence the patient's survival. Surgical thrombectomy and complete resection of the primary cancer should be considered for a better prognosis \[[@bib0005],[@bib0015]\]. We present a case of tumor thrombosis in the SMV that was treated with right hemicolectomy and greater saphenous vein grafting. To the best of our knowledge, this is the first case report of venous tumor thrombosis due to colorectal cancer that was treated by vein grafting. This work has been reported in line with the SCARE criteria \[[@bib0020]\].

2. Presentation of case {#sec0010}
=======================

A 48-year-old woman was initially admitted to a nearby hospital due to anemia. Total colonoscopy and computed tomography (CT) revealed ascending colon cancer accompanied with tumor thrombosis in the SMV. Subsequently, the patient was referred to our department for surgical treatment.

Her medical history was unremarkable. Complete blood count showed white blood cell count and hemoglobin level of 7850/μl and 12.1 g/dL, respectively. Serum biochemistry test results were as follows: aspartate aminotransferase, 17 U/L; alanine aminotransferase, 19 U/L; total bilirubin, 0.1 mg/dL; carcinoembryonic antigen, 341.9 ng/mL; cancer antigen 19-9, 3 U/mL; and C-reactive protein, 0.18 mg/dL. The coagulation marker D-dimer level was 0.7 μg/mL.

Total colonoscopy revealed a type 2 tumor in the ascending colon, and moderately differentiated adenocarcinoma was diagnosed by examining the biopsy specimen ([Fig. 1](#fig0005){ref-type="fig"}a). Computed tomography (CT) showed an enhanced mass in the ascending colon and an intraluminal filling defect from the ileocolic vein to the SMV ([Figs. 1](#fig0005){ref-type="fig"}b and 2a). On positron emission tomography-computed tomography (PET-CT), abnormal fluorodeoxyglucose (FDG) uptake was observed in the ascending colon (SUV-max: 23.1). Abnormal FDG uptake extended from the ileocolic vein to the SMV (SUV-max: 9.4) ([Fig. 2](#fig0010){ref-type="fig"}b).Fig. 1Images of the colon tumor.(a) Total colonoscopy reveals a type 2 tumor in the ascending colon. (b) Computed tomography (CT) shows an enhanced mass in the ascending colon without distant metastasis.Fig. 1Fig. 2Images of the tumor thrombosis.(a) Contrast-enhanced CT shows an intraluminal filling defect from the ileocolic vein to the superior mesenteric vein (SMV; white arrow). (b) On PET-CT, abnormal FDG uptake extended from the ileocolic vein (ICV) to the SMV (SUV-max: 9.4).Fig. 2

The patient was diagnosed with ascending colon cancer with tumor thrombosis in the SMV. The preoperative staging was T4aN1M0, stage IIIB (TNM classification). After admission, preoperative pharmacological prophylaxis was initiated with unfractionated heparin (15,000 unit/day) to prevent extension of thrombosis. Surgical resection was performed on the sixth inpatient day. Tumor thrombosis extended from the ileocolic vein to the root of the SMV. Right hemicolectomy with D3 lymphadenectomy, tumor thrombectomy of the SMV, and greater saphenous vein grafting were performed ([Fig. 3](#fig0015){ref-type="fig"}). The duration of surgery was 334 min, and the blood loss was 210 mL.Fig. 3Intraoperative findings.(a) Tumor thrombosis extended from the ileocolic vein (ICV) to the root of the SMV. (b) Scheme of the tumor thrombosis. (c) After ligation of ICV and thrombectomy, greater saphenous vein grafting was performed. (d) Scheme of the vein grafting.Fig. 3

Pathological examination showed that the tumor was a moderately differentiated adenocarcinoma of the ascending colon, which reached the subserosal layer, with no lymph node metastasis (0/35) or lymphatic duct involvement (ly0) but with venous involvement (v2) ([Fig. 4](#fig0020){ref-type="fig"}). The pathological staging was T3N0M0, stage IIA (TNM classification). Contrast-enhanced CT was performed to confirm patency of the reconstructed vein on the seventh postoperative day. Remnant tumor thrombosis or vein stricture was not detected in the CT image ([Fig. 5](#fig0025){ref-type="fig"}a). The postoperative course was uneventful, and the patient was discharged on the eighth postoperative day. Eight courses of chemotherapy with capecitabine plus oxaliplatin were initiated 6 weeks postoperatively and continued for 6 months. Currently, 17 months have passed after the surgery, and no recurrence has been detected to date ([Fig. 5](#fig0025){ref-type="fig"}b).Fig. 4Pathological findings of the resected specimen.(a) Macroscopic findings of the ileum and ascending colon. Tumor is indicated by a white arrow. (b) Resected specimen of the ICV. (c) Hematoxylin and eosin (HE) staining of the ICV shows intraluminal invasion of moderately differentiated adenocarcinoma. (d) HE staining of a colon tumor shows a moderately differentiated adenocarcinoma reaching the subserosal layer. (e) Venous involvement (v2) is confirmed (CD 31) by immunohistochemistry.Fig. 4Fig. 5Postoperative findings.(a) The patency of the reconstructed vein was sustained and remnant tumor thrombosis was not detected on the seventh postoperative day. (b) No recurrence has been confirmed at 17 months follow-up CT imaging.Fig. 5

3. Discussion {#sec0015}
=============

Intraluminal tumor thrombus in the mesenteric vein originating from colorectal cancer is a rare condition \[[@bib0005]\]. Sato et al. reported that the incidence of advanced colorectal carcinoma with venous tumor thrombosis was 1.7% \[[@bib0025]\]. In contrast, tumor thrombosis in the portal vein system is a frequent complication of hepatocellular carcinoma because of its hypervascularization \[[@bib0005]\]. Otani et al. reported that the number of reports on venous tumor thrombosis is increasing owing to the advancement of diagnostic imaging technology \[[@bib0010]\]. 18F-FDG-PET may be useful for the differential diagnosis between tumor thrombus and venous thrombus \[[@bib0030]\].

[Table 1](#tbl0005){ref-type="table"} shows the reported cases of colon cancer accompanied with tumor thrombosis in the SMV and IMV in the Japanese population \[[@bib0015],[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. Including our case, seven and five cases in the SMV and the IMV, respectively, have been reported. Based on the reported cases, the ascending colon and the rectum were the most common tumor sites developing tumor thrombosis. With regard to SMV tumor thrombosis, the most common histological type was moderately differentiated adenocarcinoma (five of seven cases). After surgical treatment, liver metastatic recurrence occurred in four of 12 cases (25%). Given this, venous tumor thrombosis is likely to increase the risk of liver metastasis from primary colorectal cancer. Considering micrometastasis, adjuvant chemotherapy should be performed even after complete surgical tumor resection \[[@bib0010],[@bib0065]\].Table 1Reported cases of colon cancer accompanied with tumor thrombosis in the mesenteric veins.Table 1**case**Age/Sexlocationhistologic type lymphovascular invasionTNMStageSurgical treatmenttreatment for tumor thrombosisadjuvant chemotherapyrecurrenceprognosisyearFirst Author150/FAmoderately differentiated adenocarcinomaN.D.right hemicolectomypartial resection of SMVoral 5-FUliver, lung, pelvisdead (5 M)1993Tomono268/MS, Ramoderately differentiated adenocarcinoma ly3, v2N.D.low anterior resectionligation of IMV(--)(--)alive (24 M)2000Fujii378/FApoorly differentiated adenocarcinoma ly3, v3330IIIbright hemicolectomy, partial resection of duodenum and small bowelremoval of tumor thrombosis from SMV incision5-FU/LVliver metastasis (4 M)dead (5 M)2007Kawashima468/MTmoderately differentiated adenocarcinoma ly2, v34a10IIIaright hemicolectomyremoval of tumor thrombosis from SMV incisionFOLFOX4, UFT/LV(--)alive (24 M)2009Kanzaki566/FAmoderately differentiated adenocarcinoma ly2, v34b10IIIaright hemicolectomy, partial resection of duodenumpartial resection of SMVFOLFIRI(--)alive (22 M)2009Yamagami666/MRamoderately differentiated adenocarcinoma ly1, v3310IIIalow anterior resectionligation of IMVmFOLFOX(--)alive (6 M)2012Nasu754/FRawell differentiated adenocarcinoma ly1, v2300IIlow anterior resectionligation of IMVTS-1, FOLFOX4+Bevliver (8 M) lung (33 M)alive (50 M)2012Jimi870/FAwell differentiated adenocarcinoma ly1, v14b10IIIaright hemicolectomy, partial resection of duodenum and small bowelpartial resection of SMVFOLFOX4(--)alive (9 M)2015kamata969/FRswell differentiated adenocarcinoma ly1, v3310IIIalow anterior resectionligation of IMVmFOLFOX6lung (18 M)alive (36 M)2015Matsumura1067/MSwell differentiated adenocarcinoma ly1, v3311IIIasigmoidectomy, liver resectionligation of IMVmFOLFOX6+Bev(--)alive (7 M)1160/FAmoderately differentiated adenocarcinoma ly3, v34b00IIpartial resection of transverse colon and small bowelremoval of tumor thrombosis from SMV incision(--)liver metastasis and disseminationdead (21 M)2016TajimaOur case48/FAmoderately differentiated adenocarcinoma ly0, v2300IIright hemicolectomygreater saphenous vein grafting of SMVCapeOx(--)alive (17 M)2018[^1]

Before surgical treatment, accurate assessment of the range of tumor thrombosis and collateral circulation in contrast-enhanced CT is necessary \[[@bib0040]\]. Initial ligation of the center side vein may be essential to prevent migration of tumor thrombosis \[[@bib0010],[@bib0035]\].

In the surgical treatment of tumor thrombosis in the SMV, which is a requisite drainage vein of the small bowel, we need to consider short bowel syndrome \[[@bib0065]\]. We were able to perform thrombectomy close to the root of the SMV using the greater saphenous vein graft. Massive small bowel resection was avoided by this procedure. To the best of our knowledge, this is the first case report of venous tumor thrombosis due to colorectal cancer treated by vein grafting.

4. Conclusion {#sec0020}
=============

Here, we present a case of ascending colon cancer accompanied with tumor thrombosis in the SMV that was treated with right hemicolectomy and greater saphenous vein grafting. In cases of venous tumor thrombosis, a well-planned surgical strategy and systemic chemotherapy are required for a better prognosis.
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[^1]: M, male ; F, female ; N.D., not described A, ascending colon; T, transverse colon; S, sigmoid colon; Rs, rectosigmoid; Ra, rectum above the peritoneal reflection 5-FU, fluorouracil; LV, leucovorin; UFT, tegafur-uracil; Bev, Bevacizumab FOLFOX, oxaliplatin/5-FU/leucovorin; FOLFIRI, irinotecan/5-FU/leucovorin; CapeOx,capecitabine/oxaliplatin.
